OLCEGEPANT

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
UNII WOA5J8TX6M
EPA CompTox DTXSID10174443

Structure

InChI Key ITIXDWVDFFXNEG-JHOUSYSJSA-N
Smiles NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(N2Cc3ccccc3NC2=O)CC1)C(=O)N1CCN(c2ccncc2)CC1
InChI
InChI=1S/C38H47Br2N9O5/c39-29-21-25(22-30(40)34(29)50)23-33(45-37(53)48-15-10-28(11-16-48)49-24-26-5-1-2-6-31(26)44-38(49)54)35(51)43-32(7-3-4-12-41)36(52)47-19-17-46(18-20-47)27-8-13-42-14-9-27/h1-2,5-6,8-9,13-14,21-22,28,32-33,50H,3-4,7,10-12,15-20,23-24,41H2,(H,43,51)(H,44,54)(H,45,53)/t32-,33+/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C38H47Br2N9O5
Molecular Weight 869.66
AlogP 4.41
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 5.0
Number of Rotational Bond 12.0
Polar Surface Area 176.47
Molecular species BASE
Aromatic Rings 3.0
Heavy Atoms 54.0

Bioactivity

Mechanism of Action Action Reference
Calcitonin gene-related peptide type 1 receptor antagonist ANTAGONIST PubMed PubMed
Protein: Calcitonin gene-related peptide type 1 receptor
Description: Calcitonin gene-related peptide type 1 receptor
Organism : Homo sapiens
Q16602 ENSG00000064989
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Membrane receptor Family B G protein-coupled receptor Peptide receptor (family B GPCR) Calcitonin-like receptor Calcitonin gene-related peptide receptor
0 0-4 0-0 0-0 -
Other membrane protein
- 0-0 - 0-0 -
Secreted protein
- - - 0 -
Assay Description Organism Bioactivity Reference
Displacement of [125I]CGRP from human cloned CLR/RAMP1 receptor expressed in E10 cells Homo sapiens 0.005 nM
Antagonist activity at human cloned CLR/RAMP1 receptor expressed in E10 cells measured as inhibition of CGRP-mediated cAMP production Homo sapiens 0.1 nM
Displacement of [125I]adrenomedullin form CGRP receptor in human SK-N-MC cell membrane by competitive binding assay Homo sapiens 0.014 nM
Displacement of [125I]CGRP from CGRP receptor in human SK-N-MC cells after 180 mins by gamma counting Homo sapiens 0.014 nM
Displacement of [125I]CGRP from CGRP receptor in rat spleen homogenate after 180 mins by gamma counting Rattus norvegicus 3.4 nM
Displacement of [125I]CGRP from CGRP receptor in human SK-N-MC cells Homo sapiens 0.02 nM
Displacement of [125I]-CGRP from CGRP receptor in human SK-N-MC cells Homo sapiens 0.01 nM
Antagonist activity at human CGRP receptor Homo sapiens 0.01 nM
Displacement of [125I]CGRP from CGRP receptor in human SK-N-MC cell membranes preincubated for 30 mins followed by radioligand addition measured after 2 hrs by liquid scintillation counting Homo sapiens 0.01 nM
Antagonist activity at CGRP receptor in human SK-N-MC cells assessed as inhibition of CGRP-stimulated cAMP production preincubated for 30 mins followed by CGRP addition measured after 3 hrs by beta-lactamase reporter gene-based FRET assay Homo sapiens 4.0 nM
Antagonist activity at CGRP receptor in human SK-N-MC cells assessed as inhibition of alpha-CGRP-induced c-AMP formation after 15 mins by radioimmunoassay Homo sapiens 0.026 nM
Antagonist activity against human CGRP receptor Homo sapiens 0.03 nM
Binding affinity to human CGRP receptor Homo sapiens 0.014 nM
Binding affinity to rat CGRP receptor Rattus norvegicus 3.4 nM
Antagonist activity against CGRP receptor assessed as inhibition of CGRP-mediated vasorelaxation in human cerebral arteries Homo sapiens 0.07943 nM
Antagonist activity against CGRP receptor assessed as inhibition of CGRP-mediated vasorelaxation in human coronary arteries Homo sapiens 0.03981 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 16.75 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 9.15 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 2.49 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 4.63 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.04 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.04 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.26 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.04 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.04 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.26 %
Displacement of [3H]telcagepant from recombinant human CLR/RAMP1 expressed in Sf21 insect cell membranes measured after 60 mins by microbeta scintillation counting method Homo sapiens 0.03162 nM
Inhibition of human CLR/RAMP1 Homo sapiens 0.03 nM
Inhibition of rat CGRP receptor Rattus norvegicus 6.4 nM

Cross References

Resources Reference
ChEMBL CHEMBL207197
DrugBank DB04869
FDA SRS WOA5J8TX6M
Guide to Pharmacology 702
PDB 3N6
PubChem 6918509
SureChEMBL SCHEMBL2252127
ZINC ZINC000098052868
CONTENTS